샘플 요청 목록

 카트 문의
시장보고서
상품코드
1792815

세계의 주산기 감염 시장

Perinatal Infections
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 397 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

주산기 감염 세계 시장은 2030년까지 19억 달러에 달할 전망

2024년에 16억 달러로 추정되는 주산기 감염 세계 시장은 2024-2030년 분석 기간 동안 CAGR 3.7%로 성장하여 2030년에는 19억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 자연 감염은 CAGR 4.8%를 기록하며 분석 기간 종료시에는 6억 2,640만 달러에 달할 것으로 예측됩니다. 거대세포바이러스 감염 분야의 성장률은 분석 기간 동안 CAGR 2.8%로 추정됩니다.

미국 시장은 4억 2,310만 달러로 추정, 중국은 CAGR 7.0%로 성장 예측

미국의 주산기 감염 시장은 2024년에 4억 2,310만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 3억 9,080만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.4%와 2.9%로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 것으로 예측됩니다.

세계의 주산기 감염 시장 - 주요 동향과 촉진요인 정리

주산기 감염이 신생아 및 산모 건강에서 중요한 관심사인 이유는 무엇일까?

주산기 감염이란 태아나 신생아가 자궁 내, 분만 중, 출생 직후에 감염되는 것을 말합니다. 일반적인 병원체로는 B군 연쇄상구균, 리스테리아균, 대장균, 사이토메갈로바이러스, 단순포진바이러스, 풍진 등이 있습니다. 이러한 감염은 신생아 패혈증, 수막염, 폐렴, 사산, 장기적인 발달 장애 등 심각한 합병증을 유발할 수 있습니다.

조기 발견과 적시 개입은 산모와 신생아의 예후를 개선하는 데 필수적입니다. 그러나 많은 주산기 감염은 무증상 또는 비특이적 증상을 보여 진단을 어렵게 합니다. 전 세계 보건 시스템은 특히 감염 관련 사망률이 여전히 높은 저자원 환경에서 산전 선별검사, 백신 접종, 분만 시 감염 관리를 강화해야 할 필요성이 대두되고 있습니다.

전 세계적으로 검진 및 예방 전략은 어떻게 진화하고 있는가?

산전관리에서는 HIV, B형 간염, 매독, B군 연쇄상구균 등 주요 감염성 질환에 대한 스크리닝이 정기적으로 이루어지고 있습니다. 중합효소 연쇄 반응(PCR) 및 기타 분자 기술은 자궁 내 감염의 진단 민감도와 진단 시간을 개선하고 있습니다. 특히 B군 연쇄상구균에 대한 분만 중 항생제 예방(IAP)은 조기 신생아 패혈증 감소에 효과적임이 입증되었습니다.

예방에 있어서 백신 접종의 역할이 점점 더 커지고 있습니다. 독감, 백일해, B형 간염에 대한 산모의 예방접종은 산모와 신생아를 모두 보호하는 데 도움이 됩니다. 호흡기세포융합바이러스(RSV), B군 연쇄상구균, 사이토메갈로바이러스에 대한 모체 백신에 대한 연구도 진행 중입니다. 현장 검사 도구와 디지털 산모 건강 플랫폼은 농촌 지역과 의료 서비스가 부족한 지역에서 감염성 질환 관리에 대한 접근성을 높이는 데 도움이 되고 있습니다.

공중 보건 프로그램과 임상 투자의 초점은 어디에 집중되어 있는가?

고소득 국가에서는 주산기 감염을 관리하기 위한 프로토콜이 확립되어 있지만, 중저소득 국가에서는 산전 검사 및 임산부 예방접종 프로그램의 규모가 확대되고 있습니다. 공중보건기관, NGO, 모자보건단체는 임산부 관리, 출산 준비, 감염 감시를 위한 역량 개발에 투자하고 있습니다.

병원, 산부인과 진료소, 신생아 중환자실에서는 신속한 진단 도구와 항균제 관리 전략을 통합하고 있습니다. 임상연구는 병원체 특이적 검사법 개선, 수직감염 관리를 위한 치료법, 산모용 백신에 중점을 두고 있습니다. 민간 부문에서는 주산기 의료 현장에 맞는 진단키트, 멀티플렉스 PCR 패널, 감염 위험도 점수화 알고리즘 개발이 진행되고 있습니다.

주산기 감염 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

주산기 감염 시장의 성장은 감염 관련 신생아 사망률에 대한 인식 증가, 산전 선별검사 프로그램 확대, 임산부 예방접종 전략의 발전 등의 요인에 의해 이루어질 것으로 예상됩니다. 신생아 패혈증을 줄이고 사산을 예방하기 위한 전 세계적인 노력으로 감염 관리 도구와 산과 진단 약품에 대한 수요가 증가하고 있습니다.

분자 검사 기술의 첨단 패키징, 현장 진단 솔루션의 확대, 보편적 산모 관리 패키지에 주산기 감염 검진을 포함하는 것도 시장 확대에 기여하고 있습니다. 또한, 산모 백신에 대한 규제 강화와 저소득 국가의 의료 인프라에 대한 투자도 예방 및 관리 솔루션의 보급에 기여하고 있습니다.

부문

감염 유형(자연 감염, 거대세포바이러스 감염, 엔테로바이러스 감염, 음부포진 감염, 임질 감염, 인간면역결핍바이러스 감염, 풍진 감염, 매독 감염, 기타 감염), 치료(항생제 치료, 항바이러스 치료, 항레트로바이러스 치료, 기타 치료), 최종사용자(병원·진료소 최종사용자, 외래 수술 센터 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • bioMerieux
  • Bio-Rad Laboratories
  • Cepheid
  • Danaher Corporation
  • DiaSorin S.p.A.
  • EKF Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Merck & Co., Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • QuidelOrtho Corporation
  • Revvity, Inc.(formerly part of PerkinElmer)
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Trinity Biotech
  • Vircell S.L.
  • ZEUS Scientific, Inc.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.25

Global Perinatal Infections Market to Reach US$1.9 Billion by 2030

The global market for Perinatal Infections estimated at US$1.6 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Natural Infection, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$626.4 Million by the end of the analysis period. Growth in the Cytomegalovirus Infection segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$423.1 Million While China is Forecast to Grow at 7.0% CAGR

The Perinatal Infections market in the U.S. is estimated at US$423.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$390.8 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Perinatal Infections Market - Key Trends & Drivers Summarized

Why Are Perinatal Infections a Critical Concern in Neonatal and Maternal Health?

Perinatal infections refer to infections acquired by the fetus or newborn either in utero, during labor and delivery, or shortly after birth. Common pathogens include Group B Streptococcus, Listeria monocytogenes, Escherichia coli, cytomegalovirus, herpes simplex virus, and rubella. These infections can lead to severe complications such as neonatal sepsis, meningitis, pneumonia, stillbirth, or long-term developmental impairments.

Early detection and timely intervention are essential for improving maternal and neonatal outcomes. However, many perinatal infections are asymptomatic or show nonspecific signs, making diagnosis challenging. Global health systems are under growing pressure to enhance prenatal screening, vaccination, and intrapartum infection control, especially in low-resource settings where infection-related mortality remains high.

How Are Screening and Prevention Strategies Evolving Globally?

Prenatal care increasingly includes routine screening for key infectious agents like HIV, hepatitis B, syphilis, and Group B strep. Polymerase chain reaction (PCR) and other molecular techniques are improving diagnostic sensitivity and turnaround time for intrauterine infections. Intrapartum antibiotic prophylaxis (IAP), particularly for Group B strep, has proven effective in reducing early-onset neonatal sepsis.

Vaccination plays a growing role in prevention. Maternal immunization against influenza, pertussis, and hepatitis B helps protect both mother and newborn. Research is advancing in maternal vaccines for respiratory syncytial virus (RSV), Group B strep, and cytomegalovirus. Point-of-care testing tools and digital maternal health platforms are helping expand access to infection management in rural and underserved areas.

Where Is the Focus of Public Health Programs and Clinical Investment Concentrated?

High-income countries have well-established protocols for managing perinatal infections, while middle- and low-income countries are scaling up prenatal testing and maternal immunization programs. Public health agencies, NGOs, and maternal-child health organizations are investing in capacity building for antenatal care, birth preparedness, and infection surveillance.

Hospitals, obstetric clinics, and neonatal intensive care units are integrating rapid diagnostic tools and antimicrobial stewardship strategies. Clinical research is focusing on improved pathogen-specific assays, therapies to manage vertical transmission, and maternal vaccines. The private sector is developing diagnostic kits, multiplex PCR panels, and infection risk scoring algorithms tailored to perinatal care settings.

Growth in the Perinatal Infections market is driven by several factors…

Growth in the perinatal infections market is driven by factors such as rising awareness of infection-related neonatal mortality, expansion of prenatal screening programs, and progress in maternal immunization strategies. Global initiatives to reduce neonatal sepsis and prevent stillbirths are intensifying demand for infection control tools and obstetric diagnostics.

Advances in molecular testing technologies, increased deployment of point-of-care diagnostic solutions, and the inclusion of perinatal infection screening in universal antenatal care packages are also supporting market expansion. In addition, regulatory encouragement for maternal vaccines and investment in health infrastructure in low-income countries are contributing to wider adoption of prevention and management solutions.

SCOPE OF STUDY:

The report analyzes the Perinatal Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Infection Type (Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection, Other Infections); Treatment (Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment, Other Treatments); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • bioMerieux
  • Bio-Rad Laboratories
  • Cepheid
  • Danaher Corporation
  • DiaSorin S.p.A.
  • EKF Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Merck & Co., Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • QuidelOrtho Corporation
  • Revvity, Inc. (formerly part of PerkinElmer)
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Trinity Biotech
  • Vircell S.L.
  • ZEUS Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Perinatal Infections - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Maternal Infections During Pregnancy Spurs Demand for Early Detection and Treatment Solutions
    • Increased Awareness of Congenital Infection Risks Strengthens Emphasis on Screening Protocols and Preventive Therapies
    • Growth in Preterm Births and Low Birth Weight Incidences Throws the Spotlight on Infection-Linked Perinatal Complications
    • Expansion of Point-of-Care Testing and Rapid Diagnostics Supports Timely Identification of Vertical Transmission Pathogens
    • OEM Innovation in Multiplex PCR and Serological Assays Enhances Accuracy of Perinatal Infection Screening Panels
    • Rising Demand for Antiviral, Antibacterial, and Antifungal Therapies Tailored for Pregnant Women Supports R&D Pipelines
    • Advancements in Vaccine Development for CMV, GBS, and Zika Offer Long-Term Solutions for Maternal-Fetal Protection
    • Global Focus on Reducing Neonatal Mortality Encourages Adoption of Preventive Antenatal Infection Management Protocols
    • Digitalization of Maternal Health Records and Surveillance Platforms Strengthens Epidemiological Tracking of Infections
    • Increased Research on Microbiome Imbalance in Pregnancy Promotes Exploration of Probiotic-Based Preventive Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Perinatal Infections Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Perinatal Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Perinatal Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Perinatal Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Natural Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Natural Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Natural Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cytomegalovirus Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cytomegalovirus Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cytomegalovirus Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Enterovirus Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Enterovirus Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Enterovirus Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Genital Herpes Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Genital Herpes Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Genital Herpes Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gonorrhea Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gonorrhea Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gonorrhea Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Human Immunodeficiency Virus Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Human Immunodeficiency Virus Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Human Immunodeficiency Virus Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Rubella Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Rubella Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Rubella Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Syphilis Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Syphilis Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Syphilis Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Antibiotic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Antibiotic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Antibiotic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Antiviral Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Antiretroviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Antiretroviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Antiretroviral Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Perinatal Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Perinatal Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Perinatal Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: France 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: France 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 128: UK Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Spain 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Russia 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Perinatal Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Perinatal Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Australia 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 185: India Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: India 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 188: India Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: India 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: India 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: South Korea 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Perinatal Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Perinatal Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Perinatal Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Argentina 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Brazil 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Mexico 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Perinatal Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Perinatal Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Perinatal Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Iran 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Israel 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: UAE 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Perinatal Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Perinatal Infections by Infection Type - Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 319: Africa 16-Year Perspective for Perinatal Infections by Infection Type - Percentage Breakdown of Value Sales for Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection and Other Infections for the Years 2014, 2025 & 2030
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Perinatal Infections by Treatment - Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Perinatal Infections by Treatment - Percentage Breakdown of Value Sales for Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Perinatal Infections by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Perinatal Infections by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제